A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model

The blockade of programmed cell death-1 (PD1) and its ligand PDL1 has been proven to be a successful immunotherapy against several cancers. Similar to cancer, PD1 contributes to the establishment of several chronic infectious diseases, including malaria. While monoclonal antibodies (mAbs) targeting...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Phares, Timothy W., Kotraiah, Vinayaka, Karunarathne, Deshapriya S., Huang, Jing, Browne, Cecille D., Buontempo, Peter, Mansour, Marc, Noe, Amy R., Wykes, Michelle N., Pannucci, James, Tsuji, Moriya, Gutierrez, Gabriel M.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7363839/
https://ncbi.nlm.nih.gov/pubmed/32733457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01377
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars